Approval of Daclizumab withdrawn
Recently, the company Biogen, in consultation with the European Medicines Agency (EMA), withdrew the approval of the MS drug Daclizumab. The reason was that, in addition to a death due to an autoimmune liver inflammation,
Continue reading





